Neal's got a box sitting on his bathroom counter. His doctor wrote the script 3 days ago. It's still unopened. His buddy at the gym won't stop talking about the one he's on. His wife lost thirty pounds on hers in four months. Neal's labs aren't where he wants them either. Part of him wants this box to be the answer. Part of him doesn't trust it yet. If that's you too, this episode is for you. Ozempic, Wegovy, Mounjaro, Zepbound. One in eight adults in this country is currently on one of these drugs. Coach Brian breaks down the real research behind them, the actual trial data, not hype and not fear. -The GOOD: the weight loss numbers, the heart protection benefit most people never hear about, and the kidney trial that could change how you think about your own labs. -The BAD: the muscle loss nobody warns you about, the real cost most guys underestimate, and what happens to your body a year after you stop. -The UGLY: the counterfeit drug problem the FDA is actively trying to shut down, the vision risk worth knowing about, and the scare that turned out to be nothing after two years of research. Every claim in this episode is backed by a real study. Full sources and links are in the show notes so you can check the work yourself. This isn't a pitch for the drug. It's not a takedown of it either. It's the full picture, so you can make the call with your own doctor instead of guessing. Before you decide anything about a GLP-1, try this first. Whether you end up on one of these drugs or not, your results still come down to what's on your plate. Lose 3 lbs in 3 Days is the exact nutrition standard Coach Brian uses with every guy inside The Call To Rise. No starving gimmicks, and no giving up your favorite foods for 3 days straight. Just a simple, laid out plan that shows you what real fat loss nutrition actually looks like, so you walk into any decision about your health with a plan already in your hands instead of another pamphlet you'll never read. Grab it free: https://thecalltorise.com/lose3lbsin3days Coach Brian Parana is not a doctor. Nothing in this episode is medical advice. Talk to your own physician before starting or stopping any medication. Fact-check sources: John Eng, Gila monster, exendin-4: VA Research, Eng and Raufman, JBC 1992, Byetta approved 2005. STEP 1 semaglutide: NEJM, 14.9% weight loss vs 2.4% at 68 weeks, 86.4% lost at least 5%. STEP 1 extension: Wilding et al., 2022, regained two-thirds of lost weight within 1 year after stopping. SURMOUNT-1 tirzepatide: NEJM, up to 22.5% avg weight loss, 52 lb at 15 mg. SURMOUNT-5: NEJM 2026, tirzepatide 20.2% loss vs semaglutide 13.7% at 72 weeks. SELECT: Nature Medicine and Lancet, 20% reduction in MACE in adults with CVD and no diabetes. FLOW: NEJM 2024, 24% reduction in kidney outcomes, 18% fewer CV events, 20% lower all-cause death. Lean mass loss: Obesity journal meta-analysis, 30.8% of weight lost was lean mass. Broader range cited: 20 to 40%. Gallbladder risk: JAMA Internal Medicine 2022 meta-analysis, 1.37x relative risk. Side effects: Ozempic data, 48% any side effect, 37% nausea. Cost: KFF late 2025, 56% say hard to afford, 27% pay full price with insurance, 14% quit due to cost. Compounding and counterfeit risk: FDA, 1,700+ adverse events as of May 2026, counterfeit Ozempic seized Dec 2025. NAION vision risk: AAO/NANOS May 2026 consensus statement, Hathaway et al., JAMA Ophthalmology. Thyroid C-cell warning: FDA clinical trial protocol data, rodent-only finding, no confirmed human cases. Pancreatitis: mixed data. Some meta-analyses show no significant risk. One 2025 meta-analysis found RR 1.44. Surgery guidance: ASA June 2023 guidance and revised October 2024 multi-society guidance. Suicidality warning: FDA January 2026, requested label removal after finding no increased risk. Foundayo orforglipron: FDA and Eli Lilly, approved April 1, 2026. Usage: Gallup and Statista late 2025, 12.4% of US adults currently using a GLP1 for weight loss.
